Turkish Journal of Medical Sciences
Volume 52

Number 1

Article 15

1-1-2022

Investigation of the expression levels of CDH1, FHIT, PTEN, and
TTPAL genes in colorectal tumors
EVRİM SUNA ARIKAN SÖYLEMEZ
ZAFER SÖYLEMEZ
MURAT ÇİLEKAR
YÜKSEL ARIKAN
ÇİĞDEM TOKYOL

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
SÖYLEMEZ, EVRİM SUNA ARIKAN; SÖYLEMEZ, ZAFER; ÇİLEKAR, MURAT; ARIKAN, YÜKSEL; TOKYOL,
ÇİĞDEM; KENGER, İBRAHİM HALİL; and SOLAK, MUSTAFA (2022) "Investigation of the expression levels
of CDH1, FHIT, PTEN, and TTPAL genes in colorectal tumors," Turkish Journal of Medical Sciences: Vol.
52: No. 1, Article 15. https://doi.org/10.3906/sag-2110-296
Available at: https://journals.tubitak.gov.tr/medical/vol52/iss1/15

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Investigation of the expression levels of CDH1, FHIT, PTEN, and TTPAL genes in
colorectal tumors
Authors
EVRİM SUNA ARIKAN SÖYLEMEZ, ZAFER SÖYLEMEZ, MURAT ÇİLEKAR, YÜKSEL ARIKAN, ÇİĞDEM
TOKYOL, İBRAHİM HALİL KENGER, and MUSTAFA SOLAK

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol52/iss1/15

Turkish Journal of Medical Sciences

Turk J Med Sci
(2022) 52: 124-130
© TÜBİTAK
doi:10.3906/sag-2110-296

http://journals.tubitak.gov.tr/medical/

Research Article

Investigation of the expression levels of CDH1, FHIT, PTEN, and TTPAL genes in
colorectal tumors
1,

1

2

Evrim Suna ARIKAN SÖYLEMEZ *, Zafer SÖYLEMEZ , Murat ÇİLEKAR ,
3
4
5
6
Yüksel ARIKAN , Çiğdem TOKYOL , İbrahim Halil KENGER , Mustafa SOLAK 
1
Department of Medical Biology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey
2
Department of General Surgery, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey
3
General Surgery Department, Park Hayat Hospital, Afyonkarahisar, Turkey
4
Department of Pathology, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey
5
Department of Medical Genetics, Faculty of Medicine, Gaziantep Islam, Science and Technology University, Gaziantep, Turkey
6
Department of Medical Genetics, Faculty of Medicine, Biruni University, İstanbul, Turkey
Received: 30.10.2021

Accepted/Published Online: 12.12.2021

Final Version: 22.02.2022

Background/aim: The main aim of the study is to assess expression levels of CDH1, FHIT, PTEN, and TTPAL genes in tumors and
peripheral bloods of colorectal cancer patients in staged I-IV.
Materials and methods: Gene expression analysis of related genes were performed for tumor tissues and peripheral blood samples of 51
colorectal cancer patients and colon tissues and blood samples of 5 healthy individuals. The real-time-PCR reaction method was used
for the analysis.
Results: Alteration of mRNA levels of related genes in tumor tissues of colorectal cancer cases was determined compared to control
tissues. GAPDH and TBP were used for the normalization. While the mRNA levels of CDH1 decreased, the mRNA level of the FHIT
and TTPAL genes increased in the tumor tissues. There was no PTEN gene expression difference in tumor tissues (total). The mRNA
levels of the CDH1 and PTEN genes were increased while the mRNA levels of FHIT and TTPAL genes decreased in the blood (total).
The mRNA levels of the CDH1 gene decreased at each stage (I-IV) in the tumor tissues and increased at each stage (I-IV) in the blood.
The PTEN gene mRNA levels at each stage were controversial. The mRNA levels of the FHIT gene increased at stage I-II-III, decreased
at stage IV in the tissues and decreased at each stage (I-IV) in the blood. The mRNA levels of TTPAL gene increased at each stage (I-IV)
in the tissues and decreased at each stage (I-IV) in the blood.
Conclusion: Although related expression levels in tissue did not correlate with its expression in blood, consistent with previous studies
FHIT and TTPAL genes upregulation and CDH1 downregulation, in especially tumoral tissues, may serve as predictive determinants
for the patients with colorectal cancer.
Key words: CDH1, FHIT, PTEN, TTPAL, colorectal tumor, gene expression

1. Introduction
Colorectal cancer (CRC) is the third most common
cancer and one of the main causes of cancer-related deaths
worldwide [1, 2]. The two main causes of CRC-related
death result from the lack of early diagnosis and metastasis
[3].
Etiologic and pathophysiologic factors of CRC are
very wide. Epithelial-mesenchymal transition (EMT) is
indispensable in the progression of these conditions [4].
The process of EMT is associated with decreased expression
of epithelial markers such as E-cadherin (CDH1) [5].
The loss of E-cadherin during the EMT process leads to

destroyed cell-cell adhesion, increased cell motility, and
advanced stages of cancer [6]. E‑cadherin is a member
of a family of homophilic transmembrane glycoproteins
expressed in almost all epithelial tissues and is responsible
for calcium (Ca+2) dependent cell-cell adhesion. It also
plays essential roles in establishing and maintaining
cell polarity, cell signaling, cellular differentiation, and
normal tissue morphology [7, 8, 9]. CDH1 dysfunction
has been reported in some of them due to allelic deletion
and mutation [10, 11]. E-cadherin inactivation leads to
activation of the β-catenin transcriptional activity [12].
Its constitutively activated form has been found in various
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human cancer types and up to 80% of tumors have a
nuclear accumulation of β-catenin in colon cancer [13].
Abnormal transcripts of Fragile Histidine Triad (FHIT)
have been found in approximately half of all esophageal,
gastric and colon carcinomas and have been reported
to be inactivated in many different types of cancer. The
encoded protein is also a tumor suppressor because loss of
its activity results in replication stress and DNA damage1.
FHIT inactivation appears to be a later event, possibly
associated with progression to more aggressive neoplasms
[14].
Tumor suppressor PTEN (phosphatase and tensin
homolog) has a leading role in a variety of processes
associated with cell survival, proliferation, and growth
[15]. In some tumors, the subcellular localization of PTEN
protein seems to mediate its activity [16]. The absence
of PTEN has been reported to be associated with more
aggressive diseases and with high degree of neoplastic
transformation, suggesting an important nuclear function
for PTEN in tumor suppression [17, 18].
TTPAL (Tocopherol alpha transfer protein-like) is
reported as a novel gene displayed hotspot mutations in
the validation set samples [19]. TTPAL is possibly involved
in the invasion and metastasis of CRC [20]. Besides, Gou et
al. [21] reported that whole genome copy number profiling
in primary colorectal tumor tissues has unravelled TTPAL
as a top amplified gene CRC [21]. It is demonstrated that
copy number gain of TTPAL leads to gene overexpression
in CRC. It was also shown that TTPAL is an oncogene by
promoting cell proliferation, migration and invasion in
vitro and animal models. TTPAL was found to activate
activated Wnt/β-catenin signalling, a key oncogenic
pathway in CRC. They also suggested that TTPAL
expression also serves as an independent prognostic
marker for CRC patients [21].
In this study, expression level of CDH1, FHIT,
PTEN, and TTPAL genes were analysed in CRC patients.
In recent years, promising studies on molecular and
biological characteristics of colorectal cancer have been
reported to help understand cancer pathogenesis. Despite
these studies, there is no definite opinion on genetic and
genomic changes and their importance for colorectal
tumorigenesis.
Recent studies on these changes will contribute to a
better understanding of colorectal cancer pathophysiology.
It can be concluded that with the early detection of
colorectal cancer as a result of a long process under the
influence of genetic and environmental factors, the patient
will have more positive results in terms of diagnosis,
prognosis and treatment. The importance of molecular
biomarkers has emerged in early stage diagnosis.
1

2. Materials and methods
2.1. Human samples
This study is a continuation of our former study [22]. Fiftyone patients (average age: 66.3 ± 12.54) with colorectal
carcinoma (stage I: 10, stage II: 19, stage III: 16, and stage
IV: 6 cases) and 5 control (average age: 62.5 ± 11.08) were
included the study. TNM and American Joint Committee
on Cancer classifications were used for the stage of cancer.
2.2. RNA extraction and real-time PCR analyses
EZ-RNA Total RNA extraction kit (BI, Israel, Cat. No:
20-400-100) was used for RNA extractions of tissues
and peripheral blood samples. Nanodrop ND-1000
spectrophotometer V3.7. was used for determining RNA
amount and RNA purity. cDNA was obtained from 1 µg of
total RNA by using iScript Reverse Transcription Supermix
(Biorad, USA, Cat. No:170884). CDH1, FHIT, PTEN, and
TTPAL genes expression levels were analysed by Rotor
Gene-Q (Qiagen, Hilden, Germany). The reaction mix
was prepared with iTaq Universal SYBR Green Supermix
(Biorad, USA, Cat. No: 1725122) and oligonucleotide
primers (designed by Genometry Biotechnology; CDH1,
TTPAL, FHIT, TBP; İzmir, TURKEY and designed by
Oligomere Biotechnology; PTEN, GAPDH; Ankara,
TURKEY). Primers were designed based on following
sequences as shown in Table.
We used the following real-time PCR protocol for
PTEN, CDH1, GAPDH: 95 °C for 30 s initial denaturation
followed by 40 cycles of 95 °C for 5 s and 60°C for 30 s;
and for FHIT, TTPAL and TBP: 95 °C for 180 s initial
denaturation followed by 35 cycles of 95 °C for 5 s, 58 °C
for 10 s and 72 °C for 20 s.
2.3. Statistical analysis
There are some freely available software packages that
support statistical analysis of expression results. REST
2009 V2.0.13 and SPSS v.19 Software [23] were used for
assessing the relative expression results.
3. Results
3.1. mRNA levels of CDH1, FHIT, PTEN, and TTPAL
genes
Alteration of mRNA levels of CDH1, FHIT, PTEN, and
TTPAL genes in tumor tissues was determined compared
to control tissues. GAPDH (Glyceraldehyde-3-Phosphate
Dehydrogenase) and TBP (TATA-Box Binding Protein)
genes were used for the normalization. While the mRNA
levels of CDH1 decreased compared to the control group
(0.247, fold regulation value: FRV) the mRNA levels of
the FHIT and TTPAL genes increased (1.722 and 1.847
FRV, respectively). There were no PTEN gene expression
differences at all tumor tissues compared to the control
(0.997; FRV) [The final gene expression results were
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Table. Primer sequences of the analysed genes.
Gene symbol

Primer sequences

CDH1-F

5’-CCCTTCCTCAAAACACACTCC-3’

CDH1-R

5’-TGGCAGTGTCTCTCCAAATC-3’

FHIT-F

5’-GGACTTTCCTGCCTCTTGGAGA- 3’

FHIT-R

5’-GCGGTCTTCAAACTGGTTGCCA-3’

PTEN-F

5’-TGGATTCGACTTAGACTTGACCT-3’

PTEN-R

5’-GGTGGGTTATGGTCTTCAAAAGG-3’

TTPAL-F

5’-CCACTCCATCTCCTCAATCAACC-3’

TTPAL-R

5’-CTCCACACACTTCACTCACACC-3’

TBP-F

5’-TCTATCCACACTCAATCTTCCTTC-3’

TBP-R

5’-CCTTCCTCCCTCTCTTATCCTC-3’

GAPDH-F

5’-CATTGCCCTCAACGACCACTTT-3’

GAPDH-R

5’-GGTGGTCCAGGGGTCTTACTCC-3’.

transformed to log values (any log base). This would make
data distribution symmetric] (Figure 1).
Alteration of mRNA levels of CDH1, FHIT, PTEN,
and TTPAL genes in peripheral blood of CRC cases were
determined compared to the control blood. The mRNA
levels of the CDH1 and PTEN genes were increased (1.355
and 1.366, FRV; respectively), while the mRNA levels of
FHIT and TTPAL genes decreased (0.580 and 0.403, FRV,
respectively) (Figure 1).
3.2. mRNA levels of CDH1, FHIT, PTEN, and TTPAL
genes at stage I-II-III-IV in tumors
The mRNA levels of the CDH1 gene decreased at all
stages (I-IV) compared to the control group [0.235; 0.369;
0.117; 0.030, FRV; respectively]. This downregulation was
significant at stage III (P < 0.001). The mRNA levels of
the PTEN gene increased at stage I-II (1.143; 1.331, FRV;
respectively), decreased at stage III-IV (0.810; 0.962, FRV;
respectively). The mRNA levels of the FHIT gene increased
at stage I-II-III (1.505; 2.006; 1.218, FRV; respectively),
decreased at stage IV (0.900, FRV). The mRNA levels of
the TTPAL gene increased at all stages (I-IV) (1.417; 1.866;
1.875; 4.567, FRV; respectively) (Figure 2).
3.3. mRNA levels of CDH1, FHIT, PTEN, and TTPAL
genes at stage I-II-III-IV in blood
The mRNA levels of CDH1 gene increased at all stages
(I-IV) compared to the control group [3.212; 1.103;
10.853; 1.523, FRV; respectively]. This upregulation was
significant at stage III (P < 0.05). The mRNA levels of the
PTEN gene also increased at stage I-II-IV compared to
the control group (1.557; 1.408; 1.455, FRV; respectively).
There were no expression differences at stage III compared
to the control (1.006; FRV). The mRNA levels of FHIT
gene decreased at all stages (I-IV) compared to the control
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group (0.618; 0.323; 0.650; 0.445, FRV; respectively). The
mRNA levels of the TTPAL gene also decreased at all
stages (I-IV) compared to the control group (0.325; 0.398;
0.282; 0.398, FRV; respectively) (Figure 3).
4. Discussion
The presented study analysed the expression of CDH1,
PTEN, FHIT, and TTPAL genes using tissue samples and
blood of patients with different stages of colorectal cancer
(CRC). Based on the information obtained from thousands
of genetic variants discovered, cancer has been shown to be
associated with other diseases and complex features. It has
been clarified that single nucleotide polymorphisms and
somatic copy number changes associated with the disease
frequently affect gene expression levels [24-27].
Genetic susceptibility to colorectal and gastric
carcinoma has been correlated with CDH1 (E-cadherin)
mutations [28-30]. Besides, infiltrative tumor growth
pattern and lymph node metastasis were associated with
loss of CDH1 expression in CRC [31]. Downregulation or
loss of E-cadherin has been suggested as a biomarker for
colorectal cancer [32]. Similarly, in our study CDH1 gene
expression downregulated in tumor tissues at all stages of
the disease compared to control tissues. On the contrary
to this result, CDH1 gene expression was upregulated
in blood samples at all stages of the disease compared
to control bloods. Methylation of EMT associated genes
is related to the progression and prognosis of CRC [33].
Zheng et al. [34] suggested that intron mutation, gene
methylation, and single nucleotide polymorphism may
also affect CDH1 expression. The discrepancy may result
from these factors reported by Zheng et al. [34].
Yazdani et al. [35] reported that PTEN expression is
important in CRC development. They found that negative
PTEN expression was statically associated with tumor
size and advanced TNM stages in patients with colorectal
carcinoma. Loss of PTEN expression was reported in
adenomas, adenomatous polyps, and CRC in some studies
[36-38]. Sun et al. [39] suggested that PTEN might be a
useful marker for the early diagnosis of CRC. They thought
that, if PTEN was downregulated in adenomas, PTEN has
to be involved in an early event during transformation.
However, Molinari and Frattini [40] suggested that “there
are conflicting results and, therefore it has not been
clarified whether PTEN might play a prognostic role in
CRC”. Although PTEN expression level tended to decrease
in CRC, a decrease of PTEN gene expression in tumor
tissue was not observed in our study.
FHIT gene expression in colon cancer was investigated
by various methods in colon cancer [41-44]. However,
studies related FHIT gene for colon cancer tumorigenesis
are limited. Wierzbicki et al. [43] found high FHIT
gene expression in adenomas and CRC. In their study,
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Figure 1. The results of real-time PCR analysis. The up/down-regulation of genes in tissues and
blood of colorectal cancer (CRC) patient were given as fold regulation levels transformed to log
values. GAPDH and TBP were reference genes for normalization.

Figure 2. The results of real-time PCR analysis. The up/down-regulation of genes in tissues of
CRC patients were given as fold regulation levels transformed to log values. GAPDH and TBP
were reference genes for normalization.

immunohistochemical analyzes showed comparable
results. Thiagalingam et al. [45] reported a very high
mRNA level of FHIT gene coding transcript in cell lines
derived from human colorectal cancers. These findings are
consistent with our study. The mRNA levels of the FHIT
gene increased at stage I-II-III. Upregulation of the FHIT
gene reported in tumor tissues was different from the blood
samples. On the contrary to these findings, Kapitanovic
et al. [46] reported that “expression of FHIT mRNA was
significantly decreased in colon tumors relative to that

in corresponding normal tissue”. However, the mRNA
levels of FHIT gene decreased at all stages (I-IV) in blood
compared to the control group in our study.
In the present study, the mRNA levels of the TTPAL
gene increased in tissues at all stages (I-IV) and decreased
in blood at all stages (I-IV). Similar to our findings,
Gou et al. [21] reported that TTPAL expression at both
mRNA and protein levels was detected in some colon
cancer cells, but not in normal colon tissues. Besides, they
reported that TTPAL mRNA expression was significantly
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Figure 3. The results of real-time PCR analysis. The up/down-regulation of genes in blood of
CRC patients were given as fold regulation levels transformed to log values. GAPDH and TBP
were reference genes for normalization.

upregulated in primary colorectal cancer tumors as
compared with their adjacent normal tissues. Besides,
Liu et al. [47] reported that the expression of TTPAL was
significantly upregulated in gastric cancer compared to
nontumor tissues. Also, suggested that DNA copy number
was positively correlated with TTPAL expression because
in the DNA copy number amplification group TTPAL
expression level was higher compared to no amplification
group. “Analysis of copy number of TTPAL in cancers
from TCGA studies demonstrated that TTPAL was
preferentially and more frequently amplified in colorectal
cancers as compared with other cancer types, suggesting
its particular involvement in colorectal cancer” [21].
We analysed the expression of mRNAs for CDH1,
PTEN, FHIT, and TTPAL by real-time PCR and observed
downregulation of CDH1 and upregulation of FHIT and
TTPAL in the tumor tissues. The expression levels of
CDH1, FHIT, and TTPAL genes expression situations
at tumoral tissues compared to control in line with
the literature. This study also reports that there was an
increase in TTPAL expression as the stage progresses in
tumor tissues of patients, but no significant difference was

observed. Although related expression levels in tissue did
not correlate with its expression in blood, consistent with
previous studies FHIT and TTPAL genes upregulation
and CDH1 downregulation, in especially tumoral tissues,
may serve as predictive determinants for the patients with
colorectal cancer. However, the clinical application of these
genes as a biomarker remains unclear for colorectal cancer.
Besides, the discordant results may result from the size of
the analysed study group or the methods of determining
gene expression levels. In conclusion, replications studies
in much larger study groups are required before suggesting
that these genes are predictive markers.
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